BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 11221837)

  • 1. Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells.
    Harada M; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
    Cancer Res; 2001 Feb; 61(3):1089-94. PubMed ID: 11221837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y; Robbins PF; Wang X; Tupesis JP; Parkhurst MR; Kang X; Sakaguchi K; Appella E; Rosenberg SA
    J Immunol; 1998 Dec; 161(12):6985-92. PubMed ID: 9862734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
    Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
    Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G
    J Immunol; 1999 Feb; 162(3):1739-48. PubMed ID: 9973437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
    Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH
    Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.
    Anichini A; Mortarini R; Maccalli C; Squarcina P; Fleischhauer K; Mascheroni L; Parmiani G
    J Immunol; 1996 Jan; 156(1):208-17. PubMed ID: 8598464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen.
    Sun Y; Song M; Stevanović S; Jankowiak C; Paschen A; Rammensee HG; Schadendorf D
    Int J Cancer; 2000 Aug; 87(3):399-404. PubMed ID: 10897046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy.
    Khong HT; Rosenberg SA
    J Immunol; 2002 Jan; 168(2):951-6. PubMed ID: 11777994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
    Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
    J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
    Riley JP; Rosenberg SA; Parkhurst MR
    J Immunol Methods; 2003 May; 276(1-2):103-19. PubMed ID: 12738363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types.
    Harada M; Li YF; El-Gamil M; Ohnmacht GA; Rosenberg SA; Robbins PF
    J Immunother; 2001; 24(4):323-33. PubMed ID: 11565834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage.
    Lupetti R; Pisarra P; Verrecchia A; Farina C; Nicolini G; Anichini A; Bordignon C; Sensi M; Parmiani G; Traversari C
    J Exp Med; 1998 Sep; 188(6):1005-16. PubMed ID: 9743519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.
    Robbins PF; El-Gamil M; Li YF; Fitzgerald EB; Kawakami Y; Rosenberg SA
    J Immunol; 1997 Jul; 159(1):303-8. PubMed ID: 9200467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
    Robbins PF; El-Gamil M; Li YF; Zeng G; Dudley M; Rosenberg SA
    J Immunol; 2002 Nov; 169(10):6036-47. PubMed ID: 12421991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
    Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
    Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes.
    Kawakami Y; Wang X; Shofuda T; Sumimoto H; Tupesis J; Fitzgerald E; Rosenberg S
    J Immunol; 2001 Feb; 166(4):2871-7. PubMed ID: 11160356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins.
    Kang X; Robbins PF; Fitzgerald EB; Wang R; Rosenberg SA; Kawakami Y
    Cancer Res; 1997 Jan; 57(2):202-5. PubMed ID: 9000554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y; Eliyahu S; Jennings C; Sakaguchi K; Kang X; Southwood S; Robbins PF; Sette A; Appella E; Rosenberg SA
    J Immunol; 1995 Apr; 154(8):3961-8. PubMed ID: 7706734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.